Isabelle Ragueneau-Majlessi, MD, MS
Dr. Ragueneau is co-founder of the University of Washington (UW) Pharmacokinetic Drug Interaction Knowledgebase Applications DIDB® and e-PKGene® and the Director of UW Drug Interaction Solutions. She received her medical degree from St Antoine University in Paris, France, and specialized in Clinical Pharmacology. Prior to moving to the US, Dr. Ragueneau designed and supervised clinical studies in the private sector and in academia for over 6 years. She started working at the University of Washington in 1999, as a Research Associate, then Principal Research Scientist and Project Manager for the Drug Interaction Database. In November 2009, Dr. Ragueneau joined the faculty of the Department of Pharmaceutics as Clinical Associate Professor and was promoted to full Professor in 2014. Dr. Ragueneau has published in the areas of drug-drug interactions (DDIs), drug disposition and clinical pharmacology. She is interested in the regulatory framework of DDI assessment and the clinical relevance of drug interactions. Dr. Ragueneau graduated from the University of Washington’s Master’s Degree Program in Biomedical Regulatory Affairs in 2010. In 2015, she was named a UW CoMotion Presidential Innovation Fellow.
Jingjing Yu, MD, PhD
Dr. Yu is the Associate Director of UW Drug Interaction Solutions. She joined the team in 2013 as a Research Scientist. Her role and responsibility have increasingly expanded to manage and supervise the database content curation process from data search to validation. Dr. Yu was promoted to be a Senior Research Scientist and the Associate Director in 2018. Dr. Yu holds an M.D. degree and a Master degree in Psychology from Peking University (Beijing, China) and a PhD degree in Biology from Rensselaer Polytechnic Institute (Troy, NY) in 2007. Prior to joining this team, Dr. Yu conducted DMPK preclinical research at Cerep (now Eurofins) followed by cancer biomarker research at UW Medicine. She is interested in safety evaluation of drugs and natural products, especially in drug interaction risk prediction, prevention, management, and clinical relevance evaluation.
Sophie Argon, PharmD, MS
Dr. Argon is the principal scientific curator and co-founder of the e-PKGene® application. She received her Master degree in Pharmacology in 1995 and her PharmD degree in 1997 from Nantes University, France. She joined the Drug Interaction Solutions team in 2007. Previously, she has worked as a clinical pharmacist in different settings in France and South America. Her area of expertise pertains to pharmacogenetic-drug interaction data.
Savannah McFeely, PhD
Dr. McFeely obtained her PhD from the department of Pharmaceutics at the University of Washington in 2019, working with the DIDB® application part of Drug Interaction Solutions, to evaluate the clinical significance and regulatory framework for the evaluation of organic anion transporting polypeptide 1B-based drug-drug interactions. Prior to her graduate studies she was a part of the DMPK department at Amgen working in clinical bioanalytical method development as well as metabolite identification for a novel peptide therapeutic. She joined the Drug Interaction Solutions team in June 2019 and is a curator of in vitro transporter-based drug interaction studies.
Katie Owens, BPharm, PhD
Dr. Owens completed a Bachelor of Pharmacy (BPharm) with Credit in 2008 and a PhD in clinical pharmacy in 2014 from the School of Pharmacy, University of Otago (Dunedin, New Zealand). Her PhD research investigated the clinical pharmacology and toxicology of paracetamol (acetaminophen) in various patient populations. This was followed by a post-doctoral research position in the area of modeling and simulation in drug development within the Division of Clinical Pharmacokinetics and Pharmacometrics, Institut de Recherches Internationales Servier (Paris, France). Katie joined the Drug Interaction Solutions team in March 2015 as a curator of preclinical and clinical drug interaction studies.
Ichiko Petrie, PharmD
Dr. Petrie received her PharmD as well as her undergraduate bachelor’s degree in Psychology from the University of Washington in 2014 and 2007, respectively. Prior to joining the Drug Interaction Solutions team, she worked as a long-term acute care hospital pharmacist at Kindred Hospital in Seattle, WA and as a clinical pharmacist/pharmacist editor at Genelex Corporation, a biotechnology company specializing in pharmacogenetics/personalized medicine and drug-drug interactions. As a Plein Geriatric Research Fellow, she led an investigation on polypharmacy and fall risk in the elderly. She also participated in a research involving Vitamin A intake and its disposition in Chronic Kidney Disease patients. Ichiko joined the Drug Interaction Solutions team in November 2016 as a curator of preclinical and clinical drug interaction studies.
Tasha Ritchie, PhD
Dr. Ritchie obtained her PhD from the department of Medicinal Chemistry at the University of Washington in 2011, focusing on the biophysical characterization of the human multidrug transporter, P-glycoprotein (P-gp). This was followed by a post-doctoral fellowship examining the structure and function of P-gp in Dr. Kenneth Linton’s laboratory at Queen Mary, University of London. Subsequently, she was appointed to Head of Service Operations at SOLVO Biotechnology, the industry leader in drug transporter products and services, where she led the contract research service laboratory in Szeged, Hungary, before joining the Drug Interaction Solutions team in May 2014 as a curator of in vitro transporter-based drug interaction studies.
Jessica Sontheimer, PhD
Dr. Sontheimer joined the Drug Interaction Solutions team in 2015 and is a curator of preclinical and clinical drug interaction studies. She completed her PhD in Pharmaceutics from the University of Washington in 2015 where she studied endogenous biomarkers of Cytochrome P450 2D6 in adult and pediatric populations. Prior to joining the DIDB, she was a major contributor of multi-institutional academic collaborations and participated in internships in the private sector. Her experience spans both the in vitro and in vivo PK/DM arenas. As part of on-going training, Dr. Sontheimer completed a certificate in clinical trials from the University of Washington in 2018.
Cheryl Wu, PhD
Research Scientist, UW Department of Pharmaceutics
Dr. Wu received her Ph.D. in Pharmaceutical Chemistry from the University of British Columbia, Canada, followed by a post-doctoral fellowship at Pfizer conducting pharmacokinetics and drug transporter research projects. Prior to joining Drug Interaction Solutions team in May 2016, she worked at a preclinical ADME-Tox/PK contract research organization (Cerep) for 17 years with increased levels of responsibilities from Senior Scientist, to Principal Scientist, to Director of Pharmaceutical Sciences, and then General Manager. During her time at Cerep, she developed in vitro ADME-Tox and in vivo rodent PK assays, served as study director for client studies, directed the service programs, and managed the CRO operations.
Cathy Yeung, PharmD, PhD, MPH
Dr. Yeung is a faculty member in the Department of Pharmacy and has been a part-time scientific curator for the Drug Interaction Knowledgebase, part of Drug Interaction Solutions, since 2008. She holds a PharmD degree from the University of Michigan, and a Ph.D. (Medicinal Chemistry) and MPH (Epidemiology) from the University of Washington. She is an investigator at the Kidney Research Institute in the Division of Nephrology (Department of Medicine). Her research interests include drug-drug interactions and the pathophysiology of altered drug metabolism and transport in patients with kidney disease.
Administrative Coordinator, UW Department of Pharmaceutics
Grace has been providing administrative support to the Drug Interaction Solutions team since 2006. Prior to joining the Department of Pharmaceutics, she worked for the UW School of Business. Grace holds a B.A. in Social Work and Psychology from University of Washington.
Licensing, UW CoMotion team